EBITDA 6,223 6,511 (4.4) 5, EBITDA

Similar documents
EBITDA 5,076 3, , EBITDA

Dalmia Bharat Enterprises

EBITDA 2,503 2,904 (13.8) 2,722 (8.0) EBITDA

Dalmia Bharat Enterprises

EBITDA 1,548 1,814 (14.7) 1,561 (0.8) EBITDA

Indian Oil Corporation

Dalmia Bharat Enterprises

Institutional Equities

ACC. Institutional Equities. Event Update. Capacity Expansion To Consolidate Presence In Central India ACCUMULATE

Sanofi India. Institutional Equities. 3QCY18 Result Update. Robust Performance BUY

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Gillette India. Institutional Equities. 1QFY18 Result Update

Jamna Auto Industries

EBITDA 1,585 1,917 (17.3) 1,673 (5.2) EBITDA

Mangalam Cement. Institutional Equities. 3QFY18 Result Update. Higher Operating costs Hurt Performance BUY

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

Colgate-Palmolive (India)

NESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

The Ramco Cements. Institutional Equities. Event Update BUY

Punjab National Bank

Indian Oil Corporation

Bata India. Institutional Equities. 1QFY19 Result Update BUY

Nestle India. Institutional Equities. 1QCY18 Result Update. Resurgence Continues BUY. Sector: FMCG CMP: Rs8,981 Target Price: Rs10,700 Upside: 19%

Thermax. Institutional Equities. 3QFY18 Result Update. Healthy Execution, But Margins Disappoint SELL

Mold-Tek Packaging. Institutional Equities. Conference Update. Promising Growth Outlook BUY

Institutional Equities

South Indian Bank. Institutional Equities. 4QFY18 Result Update. Asset Quality Pain To Ease Hereafter BUY. 15 May 2018

Punjab National Bank

Voltas. Institutional Equities. 1QFY19 Result Update. EMPS Shines, UCP Proves Its Mettle Again ACCUMULATE

Eicher Motors. Institutional Equities. Management Meet Update BUY. Reuters: EICH.NS; Bloomberg: EIM IN

Institutional Equities

Institutional Equities

26 October 2018 Reuters: MRTI.BO; Bloomberg: MSIL IN

Institutional Equities

Crisil. Institutional Equities. 3QCY17 Result Update ACCUMULATE. Weak SME Rating Revenues & Currency Movement Play Spoilsport

Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

Institutional Equities

Institutional Equities

EBITDA 5,019 4,211 5, EBITDA

Swaraj Engines. Institutional Equities. 2QFY18 Result Update ACCUMULATE

Institutional Equities

PNB Housing Finance. Institutional Equities. 4QFY18 Result Update BUY. Continued Display of Embedded Scalability. 4 May 2018

TVS Motor Company. Institutional Equities. 3QFY19 Result Update SELL

Crompton Greaves. Institutional Equities. 4QFY15 Result Update ACCUMULATE. Overseas Losses Continue; More Business Exits Likely

Hindustan Unilever. Institutional Equities. 1QFY19 Result Update

2,09,057 1,85,859 2,17, (4.1) NIM

Manappuram Finance. Institutional Equities. 3QFY18 Result Update. The Glitter Is Back In Gold Loans BUY. 9 February 2018

Consolidated Sales (Cr) Growth EBITDA (Cr) Margin PAT Margin EPS (Rs) P/E RoE

Karnataka Bank. Institutional Equities. 4QFY18 Result Update. Plucky Bank And Low Hanging Fruit BUY. 17 May Reuters: KBNK.NS; Bloomberg: KBL IN

Timken India. Institutional Equities. 4QFY16 Result Update BUY. Margin Expansion Leads To Huge Growth In Profit; Retain Buy

Hindustan Unilever. Institutional Equities. 4QFY18 Result Update

3,746 2,551 3, NIM

Dabur India. Institutional Equities. 1QFY19 Result Update

Bharat Financial Inclusion

Muthoot Finance. Institutional Equities. 1QFY18 Result Update. Gold Loan Business Continues To Glitter BUY. 10 August 2017

Dabur India. Institutional Equities. 4QFY18 Result Update. Growth Volatility Is Still Fairly High ACCUMULATE

Muthoot Finance. Institutional Equities. 3QFY18 Result Update. Funding Cost Decline Combines With Operating Leverage BUY.

Institutional Equities

Sequent Scientific. Institutional Equities. 1QFY19 Result Update BUY

IFB Industries. Institutional Equities. 3QFY18 Result Update. Healthy Revenues, Strong Gross Margin; Retain Buy BUY.

9,500 7,914 8, NIM

Institutional Equities

Institutional Equities

18,948 15,784 18, NIM

93,707 77,814 90, NIM

CARE Ratings. Institutional Equities. 2QFY18 Result Update BUY

Bajaj Electricals. Institutional Equities. 3QFY15 Result Update

Institutional Equities

Muthoot Finance. Institutional Equities. 2QFY18 Result Update BUY

Institutional Equities

Initiating Coverage. Uflex Ltd.

Bata India. Institutional Equities. Management Meet Update. On Right Track ACCUMULATE. Sector: Retail CMP: Rs692 Target Price: 696 Upside: 1%

PNB Housing Finance. Institutional Equities. 2QFY19 Result Update BUY. Relatively Soft Quarter Not Structural In Nature.

Manappuram Finance. Institutional Equities. 3QFY17 Result Update BUY

Muthoot Finance. Institutional Equities. 2QFY19 Result Update. Weak quarter not structural in any way BUY. 10 December 2018

Punjab National Bank

Punjab National Bank

Institutional Equities

Cement Sector 6 June 2018

E&P To Stay Strong; Consumer Segment To Revive

Punjab National Bank

9,251 7,812 8, NIM

9,807 8,007 9, NIM

Muthoot Finance. Institutional Equities. 1QFY19 Result Update

South Indian Bank. Institutional Equities. 1QFY19 Result Update. Performance Troughs, Pessimism Peaks BUY. 23 July 2018

La Opala RG. Institutional Equities. 4QFY17 Result Update UNDER REVIEW. Revenues Soar, But Margins Take A Hit. Sector: Tableware CMP: Rs536

Atul Auto. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Automobile CMP: Rs445 Target Price: Rs489 Upside: 10% 23 August 2017

State Bank of India. Institutional Equities. 3QFY19 Result Update BUY

Institutional Equities

State Bank of India. Institutional Equities. 1QFY18 Result Update

Hindustan Unilever. Institutional Equities. 2QFY19 Result Update

Operating expenses tracked lower than core total income growth as ABL displayed continued

Federal Bank. Institutional Equities. Management Meet Update

Cadila Healthcare. Institutional Equities. 3QFY15 Result Update UNDER REVIEW. Stable Performance. Sector: Pharmaceuticals CMP: Rs1,514

Swiss Glascoat Equipments

La Opala RG. Institutional Equities. 1QFY18 Result Update

JBF Industries. Institutional Equities. 1QFY16 Result Update BUY. Healthy Gross Profit Growth, But Other Costs Higher; Retain Buy

Ambuja Cements ACCUMULATE. Performance Highlights. CMP Target Price `207 `233. 3QCY2015 Result Update Cement. Quarterly results (Standalone)

Hindustan Unilever. Institutional Equities. 3QFY18 Result Update BUY

Transcription:

Result Update Institutional Equities Ambuja Cements 26 July 218 Reuters: ABUJ.BO; Bloomberg: ACEM IN Performance Beats Expectations, Sustainability Is Key Challenge Ambuja Cements (ACEM) reported steady revenue growth of 5.7% YoY at Rs3.2bn in, driven by volume growth. ACEM s volume at 6.41mt (above our estimate of 6.6.2mt), grew 5.6% YoY driven by strong demand in the eastern region. ACEM s realisation remained flat YoY/marginally higher QoQ at Rs 4,77/tn (Rs4,73/tn in ) against expectations of weakness because of higher sales to the individual house-building segment (83% of total sales in trade/retail segment). Contribution from sales of premium products also helped ACEM to maintain realisation YoY. Capacity utilisation improved to 88% in from 83% in, helping ACEM to control operating cost inflation to 2.9% YoY at Rs3,734/tn, largely because of lower other expenses which offset the impact of higher energy, logistics and raw material costs. However, EBITDA declined ~4% YoY to ~Rs6.2bn because of strong base-quarter performance (~Rs6.5bn in ). Effectively, EBITDA margin declined to 2.6% YoY (above our estimate of 16.8%), from 22.8% in and EBITDA/tn was pushed down by ~1% YoY to Rs971/tn (Rs1,73/tn in ). However, higher other income (contributed by ACC s diyidend) of Rs1.91bn pushed ACEM s PAT up by 27.3% YoY to Rs4.99bn. We have valued ACEM on the basis of SOTP valuation (based on replacement cost), valuing the standalone business at a replacement cost of Rs8.2bn/mt and have arrived at a target price of Rs233 (Rs227 earlier). We have retained Accumulate rating on the stock. Capacity utilisation reaches 88%: ACEM volume grew 5.6% contributed by sales in northern region (including central India) and the eastern region. The capacity utilisation touched 88% in. ACEM sold.4mt clinker in.this implies optimum capacity utilisation of the kilns and ACEM will have to rely on external clinker or source it through ACC for any further volume expansion till it adds its own capacity. Operating costs inch up by ~3% YoY: Operating costs/tn edged up by ~ 3% YoY to Rs 3,734because of higher energy, logistics and raw material costs. Logistic costs rose to Rs1,37/tn from Rs1,216/tn because of higher inter-clinker movement. Energy costs, adjusted with raw material costs, increased 3% YoY because of higher fuel prices. However strong other expenditure control is reflected in the decline to Rs4.74bn (Rs5.1bn in ) offsetting the inflation in other heads. Despite this, EBITDA/tn declined ~1% to Rs971 and EBITDAM fell to 2.6% (22.8% in ) because of outstanding base quarter () performance. Retain our estimates; introduce CY2 earnings estimate: We have retained our CY18E/CY19E EPS at Rs8.7/Rs9.7, respectively, and have introduced CY2E expecting 19% EPS growth tot Rs11.6. We have factored in volume/realisation growth of 5%/3%, respectively, for CY2E, given ACEM s capacity constraints. The new capacity is expected to be commissioned in 2HCY2 and hence we have not factored any contribution in our estimates. Outlook and rating: We have valued ACEM on the basis of SOTP valuation (based on replacement cost), valuing the standalone business at a replacement cost of Rs 8.2bn/mt and have arrived at a target price of Rs233 (Rs227 earlier). We have retained Accumulate rating on the stock. NBIE Values your patronage- Vote for The Team in the Asia Money poll 218. Click Here ACCUMULATE Sector: Cement CMP: Rs224 Target Price: Rs233 Upside: 4% Milind Raginwar Research Analyst milind.raginwar@nirmalbang.com +91-22-6273 8172 Key Data Current Shares O/S (mn) 1,985.6 Mkt Cap (Rsbn/US$bn) 443.8/6.5 52 Wk H / L (Rs) 292/189 Daily Vol. (3M NSE Avg.) 3,371,13 Price Performance (%) 1 M 6 M 1 Yr Ambuja Cements 5.4 (15.) (15.6) Nifty Index 3.7.9 11.4 Source: Bloomberg Y/E December (Rsmn) YoY % QoQ % Net sales 3,169 28,545 5.7 28,626 5.4 Operating expenses (23,946) (22,35) 8.7 (23,555) 1.7 EBITDA 6,223 6,511 (4.4) 5,71 22.7 EBITDA margin (%) 2.6 22.8 (218.) 17.7 291.3 Other income 1,911 56 241.3 57 276.8 Interest costs 192 165 16.4 257 (25.4) Depreciation 1,364 1,439 (5.2) 1,393 (2.) PBT 6,578 5,467 2.3 3,928 67.5 Non-recurring items - - - - - PBT (after non-recurring items) 6,578 5,467 2.3 3,928 67.5 Tax 1,586 1,544 2.7 1,11 56.9 Reported PAT 4,993 3,923 27.3 2,918 71.1 Adjusted PAT 4,993 3,923 27.3 2,918 71.1 NPM (%) 16.5 13.7 28.7 1.2 635.6 Adjusted EPS (Rs) 2.5 2. 27.3 1.5 71.1

Exhibit 1: Operational details YoY % QoQ % E Deviation % Volume (mnmt) 6.41 6.7 5.6 6.22 3.1 6.2 3.4 Cement realisation (Rs/mt) 4,77 4,651 1.2 4,595 2.4 4,575 2.9 Operating costs (Rs/mt) 3,734 3,641 2.5 3,787 (1.4) 3,86 (1.9) EBITDA (Rs/mt) 971 1,1 (3.9) 814 19.3 769 26.3 Exhibit 2: Detailed financials (Rsmn) YoY % QoQ % E Deviation % Net sales 3,169 28,545 5.7 28,626 5.4 28,37 6.3 Expenditure Change in stock 784 79 896.8 586 33.7 21 273.1 Raw material (2,882) (2,379) 21.2 (2,74) 6.6 (2,698) 6.8 purchased products (14) - n.a - n.a - n.a Power & fuel costs (6,547) (5,647) 15.9 (6,351) 3.1 (6,251) 4.7 Freight costs (8,784) (7,375) 19.1 (8,288) 6. (8,142) 7.9 Employee costs (1,758) (1,697) 3.6 (1,696) 3.7 (1,655) 6.2 Other expenses (4,744) (5,16) (5.4) (5,12) (7.) (5,67) (6.4) Total operating expenses 23,946 22,35 8.7 23,555 1.7 23,63 1.5 EBITDA 6,223 6,511 (4.4) 5,71 22.7 4,768 3.5 EBITDA margin (%) 2.6 22.8 (218) 17.7 291 16.8 382 Other income 1,911 56 241.3 57 277 55 247.4 Interest costs 192 165 16.4 257 (25) 245 (21.6) Depreciation 1,364 1,439 (5.2) 1,393 (2) 1,38 (1.2) PBT 6,578 5,467 2.3 3,928 67 3,693 78.1 Non-recurring items - - - - - - - PBT (after non-recurring items) 6,578 5,467 2.3 3,928 67 3,693 78.1 Tax 1,586 1,544 2.7 1,11 57 96 65.1 Reported PAT 4,993 3,923 27.3 2,918 71 2,733 82.7 Adjusted PAT 4,993 3,923 27.3 2,918 71 2,733 82.7 NPM (%) 16.5 13.7 281 1.2 636 9.6 692 Adjusted EPS (Rs) 2.5 2. 27.3 1.5 71 1.4 82.7 Exhibit 3: Trend in operating costs/mt Costs per mt (Rs) YoY % QoQ % Raw material costs 348 286 57 39 379 539 188 34 327 (13.6) (3.7) Power and fuel costs 799 927 816 892 93 982 1,98 1,19 1,21 9.8.2 Freight costs on sales 873 9 887 931 949 954 1,12 1,25 1,52 1.9 2.7 Inward freight costs 256 274 249 296 266 262 319 36 318 19.5 4. Total costs per mt 3,333 3,698 3,737 3,59 3,63 3,996 3,7 3,781 3,734 2.8 (1.3) 2 Ambuja Cements

Exhibit 4: Key changes to our estimates (Rsmn) Old New Change (%) CY18E CY19E CY18E CY19E Introducing CY2E Net sales 251,496 272,15 251,496 272,15 298,834 - - Operating profit 41,925 45,825 41,996 45,889 52,854.2.1 Net profit 17,247 19,349 17,246 19,34 22,975 - (.2) EPS (Rs) 8.69 9.74 8.69 9.72 11.57 - (.2) Target price (Rs) 227 233 Rating Accumulate Accumulate Source: Nirmal Bang Institutional Equities Research CY18E CY19E Exhibit 5: ACEM s target valuation ACEM s SOTP valuation: @ 2% holding company discount Based on CY19 capacity a) Target replacement cost (US$) 12 b) Currency Assumption (Rs/$) 68 c) Target replacement cost (Rs) 8,16 d) Total capacity (mt) 29.3 e) Target EV (Rsmn) 238,68 f) Total net debt (Rsmn) (16,558) g) Target m-cap (Rsmn) 255,238 h) Total equity shares O/S (mn) 1,552 i) Target price (Rs) 164 j) ACC target m-cap 269,563 k) ACEM s holding in ACC (5.5%) 134,916 l) Holding co. discount (2%) 28,332 m) Total equity shares O/S (mn) 1,552 n) ACEM's value in ACC (Rs/share) 68.7 o) Target price (Rs) 233.1 Source: Nirmal Bang Institutional Equities Research 3 Ambuja Cements

Jan-6 Sep-6 May-7 Feb-8 Oct-8 Jun-9 Mar-1 Nov-1 Jul-11 Apr-12 Dec-12 Aug-13 May-14 Jan-15 Sep-15 Jun-16 Feb-17 Oct-17 Jul-18 Jan-6 Sep-6 May-7 Feb-8 Institutional Equities Oct-8 Jun-9 Mar-1 Nov-1 Jul-11 Apr-12 Dec-12 Aug-13 May-14 Jan-15 Sep-15 Jun-16 Feb-17 Oct-17 Jul-18 Exhibit 6: Valuation charts EV/EBITDA (Rs) 45 375 3 225 15 75 EV/tn (Rs) 4 3 2 1 Price 5 9 13 17 Price $12 $16 $2 $24 $28 4 Ambuja Cements

Institutional Equities Exhibit 7: Cement capacity utilisation touches 88% in Exhibit 8: Premium products help sustain realisation YoY 1 2 4,8 15 8 5 6. 4.9 5.5 6. 5.9 4.6 5.1 6. 6.1 5. 5.9 6.2 6.41 15 1 4,6 4,4 4,2 1 5 3 5 4, (5) 3,8 (1) (3) (5) 3,6 (15) (5) Volumes (mn mt) Exhibit 9: Performance weak on strong base quarter show (1) Realisations (Rs/mt) Exhibit 1: Controlled other expenditure helps offset cost inflation 1,2 1, 8 6 4 2-57 656 552 713 988 71 579 64 1,1 616 75 814 971 4,5 4, 3,5 3, 2,5 2, 1,5 1, 5-12 1 8 6 4 2 (2) (4) (6) (8) (1) EBITDA/mt Operating costs/mt (Rs) Exhibit 11: Inflation in pet-coke prices drive energy costs higher 1,6 2 1,4 1,331 1,333 1,37 1,21 1,227 1,131 1,124 1,168 1,129 1,174 1,215 1,216 1,2 1,136 15 1, 1 8 5 6 4 2 (5) Exhibit 12: Inter-unit clinker transport pushes freight costs up 1,2 1,98 4 982 992 1,21 1,21 982 1, 927 93 3 892 858 812 799 816 2 8 1 6 4 (1) 2 (2) - (1) - (3) Freight costs/mt (Rs) Power & Fuel costs/mt (Rs) 5 Ambuja Cements

Financials Exhibit 13: Income statement Y/E December (Rsmn) CY16 CY17 CY18E CY19E CY2E Net sales 21,16 23,936 251,496 272,15 298,834 Growth (%) 114.5 14.9 8.9 8.2 9.8 Operating expenses (172,264) (197,481) (213,58) (23,49) (25,47) EBITDA 31,251 38,575 41,996 45,889 52,854 Growth (%) 1.7 23.4 8.9 9.3 15.2 Depreciation &amortisation (14,632) (12,195) (11,975) (12,6) (12,841) EBIT 21,741 29,66 32,669 36,553 42,697 Other income 5,122 3,226 2,648 2,669 2,685 Interest paid (1,45) (2,58) (2,85) (1,952) (1,949) Extraordinary/Exceptional items - - - - - PBT 19,95 27,549 3,584 34,61 4,749 Tax (5,76) (8,229) (8,283) (9,351) (1,958) Effective tax rate (%) (29) (3) (27) (27) (27) Net profit 14,19 19,32 22,31 25,249 29,791 Minority interest (2,979) (4,158) (5,54) (5,945) (6,816) Reported Net profit 11,211 15,163 17,246 19,34 22,975 Non-recurring items (386) - - - - Adjusted Net profit 11,597 15,163 17,246 19,34 22,975 Growth (%) 34.4 3.7 13.7 11.9 19. Exhibit 15: Balance sheet Y/E December (Rsmn) CY16 CY17 CY18E CY19E CY2E Cash & Bank balances 16,962 37,642 59,64 82,19 95,18 Other Current assets 89,28 99,334 1,859 111,756 121,316 Investments 1,35 2,41 1,241 1,251 1,257 Net fixed assets 218,547 214,876 211,796 2,34 24,588 Goodwill & intangible assets 1,37 779 778 777 776 Other non-current assets - - - - - Total assets 327,329 354,671 374,313 396,313 422,955 Current liabilities 77,246 9,835 93,624 96,5 99,465 Borrowings 318 331 347 364 383 Other non-current liabilities 1,534 11,392 11,62 11,853 12,9 Total liabilities 88,97 12,558 15,591 18,717 111,937 Share capital 3,971 3,971 3,971 3,971 3,971 Reserves & surplus 191,483 22,75 213,484 226,275 242,737 Shareholders' funds 239,232 252,113 268,722 287,596 311,17 Minority interest 43,778 46,8 51,267 57,35 64,39 Total equity & liabilities 327,33 354,671 374,313 396,313 422,955 Exhibit 14: Cash flow Y/E December (Rsmn) CY16 CY17 CY18E CY19E CY2E Pre-tax profit 19,95 27,549 3,584 34,61 4,749 Depreciation 11,392 (133,912) 11,975 12,6 12,841 Chg in working capital 1,849 17,537 3,731 (5,37) (5,12) Total tax paid 4,416 (2,433) (8,55) (9,119) (1,721) Other operating activities - - - - - Operating CF 127,67 (19,259) 38,235 32,181 37,767 Capital expenditure (256,179) 138,111 (8,894) (549) (17,88) Chg in investments (5,69) 1,237 (1,668) (2,724) (1,5) Other investing activities - - - - - Investing CF (261,869) 139,348 (1,562) (3,273) (18,587) FCF (134,262) 3,89 27,673 28,98 19,18 Equity raised/(repaid) 11,435 (66) 689 - - Debt raised/(repaid) 32 12 17 17 18 Dividend (incl. tax) (6,17) (9,677) (6,513) (6,513) (6,513) Other financing activities (22,59) 2,771 - - - Financing CF 122,74 (9,49) (5,675) (6,357) (6,351) Net chg in cash & bank bal. (11,522) 2,68 21,998 22,55 12,828 Closing cash & bank bal 16,962 37,642 59,64 82,19 95,18 Exhibit 16: Key ratios Y/E December CY16 CY17 CY18E CY19E CY2E Profitability and return ratios (%) EBITDAM 15.4 16.3 16.4 16.6 17.4 EBITM 1.7 12.5 12.8 13.2 14.1 NPM 5.8 6.6 6.9 7.1 7.7 RoE 6.8 6.2 6.6 6.9 7.7 RoCE 12.1 11.5 12. 12.6 13.7 RoIC 1.7 12.5 12.8 13.2 14.1 Per share data (Rs) O/s shares 1,985.7 1,985.7 1,985.7 1,985.7 1,985.7 EPS 5.8 7.6 8.7 9.7 11.6 FDEPS 5.8 7.6 8.7 9.7 11.6 CEPS 13.2 13.8 14.7 15.8 18. BV 12.5 127. 135.3 144.8 156.6 DPS 2.8 3.2 2.8 2.8 2.8 Valuation ratios (x) PE 38.4 38.4 29.3 25.8 23. P/BV 1.9 1.9 1.8 1.7 1.5 EV/EBITDA 12.8 12.8 9.9 8.5 7.3 EV/Sales 2. 2. 1.7 1.4 1.2 Other key ratios D/E (x) (.2) (.2) (.2) (.3) (.4) DSO (days) 14 15 14 14 14 Du Pont Analysis - RoE NPM (%) 5.8 5.8 6.6 6.9 7.1 Asset turnover (x).9.9.7.7.7 Equity Multiplier (x) 1.4 1.4 1.4 1.4 1.4 RoE (%) 6.8 6.8 6.2 6.6 6.9 6 Ambuja Cements

Apr-15 May-15 Jul-15 Sep-15 Nov-15 Jan-16 Mar-16 May-16 Jul-16 Sep-16 Nov-16 Jan-17 Mar-17 May-17 Jul-17 Sep-17 Nov-17 Jan-18 Mar-18 May-18 Jul-18 Institutional Equities Rating track Date Rating Market price (Rs) Target price (Rs) 26 March 218 Accumulate 228 227 6 July 218 Accumulate 27 227 26 July 218 Accumulate 224 233 Rating track graph 3 28 26 24 22 2 18 Not Covered Covered 7 Ambuja Cements

DISCLOSURES This Report is published by Nirmal Bang Equities Private Limited (hereinafter referred to as NBEPL ) for private circulation. NBEPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 214 having Registration no. INH1436. NBEPL is also a registered Stock Broker with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments. NBEPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets. NBEPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBEPL, its associates or analyst or his relatives do not hold any financial interest in the subject company. NBEPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBEPL or its associates or Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report. NBEPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBEPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company and NBEPL / analyst has not been engaged in market making activity of the subject company. Analyst Certification: Mr. Milind Raginwar, the Research Analyst is the author of this report, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations. 8 Ambuja Cements

Disclaimer Stock Ratings Absolute Returns BUY > 15% ACCUMULATE -5% to15% SELL < -5% This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBEPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of NBEPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBEPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBEPL & its group companies to registration or licensing requirements within such jurisdictions. The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBEPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBEPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. This information is subject to change without any prior notice. NBEPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBEPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries. Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBEPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBEPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report. Copyright of this document vests exclusively with NBEPL. Our reports are also available on our website www.nirmalbang.com Access all our reports on Bloomberg, Thomson Reuters and Factset. Team Details: Name Email Id Direct Line Rahul Arora CEO rahul.arora@nirmalbang.com - Girish Pai Head of Research girish.pai@nirmalbang.com +91 22 6273 817 / 18 Dealing Ravi Jagtiani Dealing Desk ravi.jagtiani@nirmalbang.com +91 22 6273 823, +91 22 6636 8833 Pradeep Kasat Dealing Desk pradeep.kasat@nirmalbang.com +91 22 6273 81/811, +91 22 6636 8831 Michael Pillai Dealing Desk michael.pillai@nirmalbang.com +91 22 6273 812/813, +91 22 6636 883 Nirmal Bang Equities Pvt. Ltd. Correspondence Address B-2, 31/32, Marathon Innova, Nr. Peninsula Corporate Park, Lower Parel (W), Mumbai-413. Board No. : 91 22 6273 8/1; Fax. : 22 6273 81 9 Ambuja Cements